AlphaMark Advisors’s CorMedix CRMD Stock Holding History

AlphaMark Advisors’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	$113K	Buy	14,000 +2,000	+17%	+$20K	0.05%	165
2024 Q3	$97K	Buy	+12,000	New	+$64.9K	0.03%	281

Other funds holding CRMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EIM

Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

FTM

First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AlphaMark Advisors's CRMD Position: Q4 2024 in Review

AlphaMark Advisors increased its CorMedix (CRMD) stake by 17% in Q4 2024, buying an estimated $20K and bringing the position to 14,000 shares worth $113K. The position accounts for 0.05% of the portfolio, ranked #165.

AlphaMark Advisors first reported a position in CRMD in Q3 2024 and has held it in 2 quarters since. 129 funds tracked by Wall St. Rank hold CRMD as of Q4 2024.

AlphaMark Advisors held 14,000 shares of CorMedix worth $113K as of Q4 2024.
AlphaMark Advisors bought 2,000 CorMedix shares in Q4 2024, an estimated $20K.
CorMedix made up 0.05% of AlphaMark Advisors's portfolio in Q4 2024, its #165 holding.
AlphaMark Advisors first reported a position in CorMedix in Q3 2024 and has held it in 2 quarters since.
129 funds tracked by Wall St. Rank held CorMedix as of Q4 2024.

Based on AlphaMark Advisors's 13F filing for Q4 2024, filed 21 Jan 2025.